Don t Try this At Home, Transcranial Magnetic Stimulation Edition

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-10-07T12:14:13.708Z • Permanent link

Deep within the confines of the National Institute of Mental Health, a team of researchers led by Dr. Mark George, a renowned psychiatrist and neuroscientist, has been working tirelessly to unravel the mysteries of depression. Their groundbreaking study, published in the Journal of Psychopharmacology, has shed new light on the treatment-resistant nature of the disorder. The breakthrough came in the form of transcranial magnetic stimulation, a non-invasive technique that uses magnetic fields to stimulate brain activity.

Researchers at the University of California, Los Angeles, have been studying the effects of transcranial magnetic stimulation on patients with treatment-resistant depression. Led by Dr. Gregory Christensen, a leading expert in the field, the team has made significant strides in understanding the neural mechanisms underlying depression. Their findings suggest that transcranial magnetic stimulation can be an effective treatment option for patients who have not responded to traditional therapies.

The FDA has taken notice of these developments, and in 2022, approved the use of transcranial magnetic stimulation for the treatment of major depressive disorder. This approval has sent shockwaves throughout the medical community, with many researchers and clinicians hailing it as a major breakthrough. The approval was made possible by the work of companies such as Neuronetics, which has developed a range of transcranial magnetic stimulation devices for clinical use.

Companies like Neuronetics are now poised to capitalize on the growing demand for transcranial magnetic stimulation treatments. The FDA's approval has opened up new revenue streams for these companies, and investors are taking notice. According to a recent report by ResearchAndMarkets, the global transcranial magnetic stimulation market is expected to reach $1.4 billion by 2025, up from $844 million in 2020. This growth is expected to be driven by increasing demand for non-invasive treatments for depression and anxiety disorders.

The research community is also taking notice of the potential of transcranial magnetic stimulation. Researchers at institutions such as the University of California, San Francisco, are now exploring the use of transcranial magnetic stimulation as a potential tool for treating a range of neurological and psychiatric disorders. This has the potential to revolutionize the field of psychiatry, offering new hope for patients who have been left behind by traditional treatments.

The approval of transcranial magnetic stimulation for the treatment of depression is part of a larger trend towards the use of non-invasive brain stimulation techniques. These techniques, which include transcranial magnetic stimulation, transcranial direct current stimulation, and transcranial alternating current stimulation, have been shown to be effective in treating a range of neurological and psychiatric disorders. The use of these techniques is becoming increasingly popular, with many researchers and clinicians now incorporating them into their treatment protocols.